Business Trends– category –
-
Virica Biotech Announces CAR-T Lentivirus Manufacturing Innovations and AAV Production Optimization with FUJIFILM
Virica Biotech Canada Overview Virica Biotech has announced innovative advancements in lentiviral vector manufacturing for CAR-T therapies, highlighted by a May 19, 2026, poster presentation featuring high productivity and smarter purifi... -
PackGene Biotech’s π-alpha 293 Platform Achieves 10x AAV Production Amplification, Up to 1e+17vg/Batch, Supporting Remedium Bio’s Gene Therapy Advancement
PackGene Biotech China Overview PackGene Biotech announced its innovative π-alpha 293 AAV high-yield platform, capable of amplifying adeno-associated virus (AAV) production up to 10-fold and achieving an impressive yield of up to 1e+17vg... -
Viral Vector Manufacturing: Global Leaders Scale Up Capacity with Advanced Platforms and Strategic Acquisitions
The Business Research Company International Overview The viral vector manufacturing market is experiencing rapid expansion as major players intensify efforts to scale production for gene therapies and vaccines. Recent strategic moves inc... -
Engineering Approaches to Modify Mesenchymal Stromal Cell (MSC) Immunomodulatory Functions: Advancing Tissue Regeneration and Clinical Application via iPSC-Derived MSCs, Cell Pre-treatment, and EV Therapeutics
PMC International Overview Engineering approaches to modify mesenchymal stromal cell (MSC) immunomodulatory functions are crucial for tissue regeneration and clinical applications. These strategies include cell pre-treatment and genetic ... -
Japan’s Healios K.K. Establishes Commercial Manufacturing System: 500L Bioreactor Operational with Minaris, Targeting 40,000 Patient Doses Annually
Healios K.K. Japan Overview Japan's Healios K.K., in its Q2 FY2026 financial results, announced the establishment of a commercial manufacturing system with Minaris and the completion of full-scale production using 50L bioreactors. Engine... -
Decentralizing CAR-T Manufacturing: Point-of-Care Production to Slash Turnaround Times and Expand Therapeutic Access
Frontiers in Immunology Switzerland Overview CAR-T cell therapy, reliant on centralized manufacturing, is resource-intensive, time-consuming, and vulnerable to logistical disruptions. Interest in decentralized or point-of-care (POC) manu... -
Chinese Scientists Achieve Breakthrough: Mass Production of 14 Million NK Immune Cells from a Single Stem Cell, Paving Way for ‘Off-the-Shelf’ Immunotherapy
Facebook (referencing a February 2026 breakthrough in China) China Overview In February 2026, Chinese scientists announced a breakthrough, successfully mass-producing an astounding 14 million natural killer (NK) immune cells in the lab f... -
Hopstem Biotech Closes ~RMB 200M Series C Funding to Accelerate Development of FDA RMAT-Designated iPSC Cell Therapy hNPC01
Insight, China's Pharmaceutical Industry China Overview Hopstem Biotechnology announced the first close of its Series C funding round, raising approximately RMB 200 million (~$40 million USD). This capital will accelerate clinical develo... -
Liv Hospital Charts Course for Scalable CAR-T Production with Comprehensive GMP and Bioreactor Guide
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive guide detailing the critical, GMP-compliant manufacturing process for CAR-T cell therapies, from T-cell collection and genetic modification to controlled expansion in... -
AstraZeneca Accelerates Next-Gen Cell Therapy Manufacturing: Gracell’s Rapid Platform Reduces Autologous CAR T Production Time
AstraZeneca UK Overview AstraZeneca is addressing critical challenges in cell therapy by accelerating autologous cell therapy manufacturing and advancing allogeneic and in vivo 'off-the-shelf' approaches. Notably, they are leveraging Gra...
